Daubert v. Merrell Dow Pharmaceuticals, Inc. — Quick Summary

Daubert v. Merrell Dow Pharmaceuticals, Inc.

509 U.S. 579 (1993)

In Brief

The landmark case of Daubert v. Merrell Dow Pharmaceuticals, Inc.

Key Issue

Does the Frye 'general acceptance' test define the admissibility of expert scientific testimony in federal trials, or should a different standard be applied under the Federal Rules of Evidence?

The Rule

Under the Federal Rules of Evidence, especially Rule 702, expert testimony must be based on scientifically valid reasoning or methodology that is relevant to the facts at issue, regardless of general acceptance in the particular field.

Bottom Line

The Supreme Court held that the Frye standard was superseded by the Federal Rules of Evidence, which require that trial judges assess the scientific validity and relevance of expert testimony. Judges are to serve as gatekeepers under Rule 702, ensuring both the reliability and relevance of expert testimony.

Why It Matters

Daubert fundamentally changed the judicial approach to evidence by broadening the admissibility criteria under the Federal Rules, enhancing the trial judge's role as a gatekeeper. The decision has wide-reaching implications, providing a more nuanced framework for handling scientific evidence. Law students must understand this case to comprehend the evolving nature of evidentiary standards and the implications for federal litigation.

Master More Evidence Cases with Briefly

Get AI-powered case briefs, practice questions, and study tools to excel in your law studies.